Intuitive Surgical Stock (US46120E6023): Q1 2026 Earnings Set for April 30 Release

Intuitive Surgical is scheduled to publish its first-quarter 2026 financial results today, April 30, after market close. Investors await updates on da Vinci system procedures and the company's latest official guidance amid strong demand for robotic-assisted surgery.

Intuitive Surgical is set to report its Q1 2026 earnings after the market closes on April 30, 2026, according to the company's investor relations schedule.

As of: April 30, 2026

By the AD HOC NEWS Editorial Team.

Intuitive Surgical's business model in brief

Intuitive Surgical develops, manufactures and sells the da Vinci surgical system, a robotic platform used in minimally invasive procedures. The company generates revenue primarily from selling instruments and accessories used with the systems, as well as recurring services.

Headquartered in Sunnyvale, California, Intuitive Surgical trades on the Nasdaq under the ticker ISRG with ISIN US46120E6023. The company reported full-year 2025 procedure growth of 14% worldwide in its annual report dated January 23, 2026.

What the latest development means for Intuitive Surgical

The upcoming Q1 2026 earnings release, scheduled for April 30, 2026, will provide insights into procedure volumes and system placements in the first quarter ended March 31, 2026. Investors are watching for commentary on demand for the da Vinci 5 system, which received FDA clearance in March 2024.

In its Q4 2025 earnings release dated January 23, 2026, Intuitive Surgical guided for full-year 2026 procedure growth of 13.5% to 15.5% at the midpoint. The company also reiterated expectations for system placements of 1,100 to 1,200 units for fiscal 2026.

The earnings conference call is set for 4:30 p.m. ET on April 30, 2026, per the investor relations page at intuitive.com.

Why Intuitive Surgical matters for U.S. investors

Intuitive Surgical is a key holding in major U.S. indexes including the S&P 500 and Nasdaq 100. The company files quarterly reports with the SEC, providing transparency for American investors.

With over 80% of its revenue from the U.S. market as stated in the 2025 10-K filing dated February 2026, Intuitive Surgical offers direct exposure to healthcare innovation and robotic surgery adoption in the world's largest medical market.

U.S. regulatory approvals, such as those from the FDA, directly impact the company's product pipeline and commercialization timelines.

Risks and open questions for Intuitive Surgical

Potential headwinds include supply chain constraints for new system production and reimbursement pressures from U.S. payers. Procedure growth could moderate if hospital capital budgets tighten amid higher interest rates.

Competition from emerging robotic surgery players remains a watch item, though Intuitive maintains a dominant installed base of over 9,000 da Vinci systems worldwide as of Q4 2025.

Bottom line

Intuitive Surgical's Q1 2026 earnings on April 30 will highlight execution against full-year guidance amid robust demand for robotic procedures. Investors await details on the path to sustained double-digit growth.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.